Michael Charles Snabes MD PhD
Reproductive Endocrinology & Infertility, STD Gynecology
Senior Medical Director, Clinical Development, General Medicine, AbbVie Pharmaceuticals
Join to View Full Profile
1 N Waukegan RdBldg 30Abbott Park, IL 60064
Dr. Snabes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Baylor College of MedicinePost-Doctoral Fellowship, 1991 - 1994- Baylor College of MedicineFellowship, Reproductive Endocrinology and Infertility, 1990 - 1992
- Baylor College of MedicineResidency, Obstetrics and Gynecology, 1987 - 1990
- Baylor College of MedicineInternship, Transitional Year, 1986 - 1987
The University of Texas Health Science Center at San AntonioClass of 1986- Baylor College of MedicinePost-Doctoral Fellowship, 1978 - 1982
University of MichiganPh.D., Physiology, 1972 - 1978
Certifications & Licensure
IL State Medical License 1998 - 2026
TX State Medical License 1987 - 2025
Awards, Honors, & Recognition
- Alpha Omega Alpha Honor Medical Society 1984
- Fellow (FACS) American College of Surgeons
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
- Join now to see all
Clinical Trials
- Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women Start of enrollment: 2008 Jan 01
- Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Start of enrollment: 2006 Dec 01
- Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Start of enrollment: 2008 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsEfficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 t...Charles E Miller, Jin Hee Kim, Robin Kroll, James A Simon, Ahmed M Soliman
American Journal of Obstetrics and Gynecology. 2024-12-01 - Impact of demographic and clinical factors on elagolix plus add-back therapy effects on patient-reported nonbleeding symptoms in women with heavy menstrual bleeding an...James A Simon, Elizabeth A Stewart, Susan Jewell, Moming Li, Michael C Snabes
F&S Reports. 2024-09-01 - 13 citationsEffect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical Trial.Shalender Bhasin, A Michael Lincoff, Steven E Nissen, Kathleen Wannemuehler, Marie E McDonnell
JAMA Internal Medicine. 2024-04-01
Press Mentions
Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for EndometriosisAugust 7th, 2020
Professional Memberships
- Fellow
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
